Results 121 to 130 of about 39,319 (333)

Combating cancer immunotherapy resistance: a nano‐medicine perspective

open access: yesCancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong   +10 more
wiley   +1 more source

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions

open access: yesHaematologica, 2019
While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing platelet aggregation response to collagen in platelet-rich plasma allowed us to identify two ...
Jennifer Series   +6 more
doaj   +1 more source

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. [PDF]

open access: yes, 2017
ROR1 (receptor tyrosine kinase-like orphan receptor 1) is a conserved, oncoembryonic surface antigen expressed in chronic lymphocytic leukemia (CLL).
A Butrym   +45 more
core   +1 more source

Extranodal diffuse large B‐cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study

open access: yesCancer Communications, EarlyView.
Abstract Background Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of aggressive non‐Hodgkin's lymphoma with distinct clinical and molecular heterogeneity. DLBCL that arises in extranodal organs is particularly linked to poor prognosis. This study aimed to determine the clinical and molecular characteristics of extranodal involvement (
Si‐Yuan Chen   +46 more
wiley   +1 more source

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

open access: yesExperimental Hematology & Oncology, 2019
Background The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models.
Alexandra Albertsson-Lindblad   +3 more
doaj   +1 more source

Predicting OCT2/MATEs‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) transporters play significant roles in the renal secretion of organic cations and drug–drug interactions (DDIs). Recent in vitro studies indicate that the Ki values for OCT2 exhibit substrate dependency and increase in potency with pre‐incubation.
Satoshi Asano   +8 more
wiley   +1 more source

Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study

open access: yesCancer Medicine, 2018
In the Asia‐Pacific region, treatment options are limited for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Xiaojun Huang   +22 more
doaj   +1 more source

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases [PDF]

open access: yes, 2017
Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors.
Berno, Tamara   +12 more
core   +1 more source

Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure.

open access: yesBlood, 2020
We previously reported durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) patients treated with CD19-targeted chimeric antigen receptor-engineered T (CD19 CAR-T) cell immunotherapy after ibrutinib failure.
J. Gauthier   +16 more
semanticscholar   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

open access: yesEuropean Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy